BFSG LLC’s Jasper Therapeutics JSPR Stock Holding History

BFSG LLC’s Portfolio JSPR Stock Details JSPR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-10	Closed	-$294	–	650
2024 Q1	$294	Buy	+10	New	+$178	﹤0.01%	639

Other funds holding JSPR

VCIM

Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return

QUSVM

Qiming U.S. Ventures Management Bellevue, Washington $55.6M AUM 98.09% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

BFSG LLC's JSPR Position: Q2 2024 in Review

BFSG LLC sold out of Jasper Therapeutics (JSPR) in Q2 2024, closing a stake of 10 shares — an estimated $294 sold.

BFSG LLC first reported a position in JSPR in Q1 2024 and held it in 1 quarter. The position peaked at $294 in Q1 2024. 69 funds tracked by Wall St. Rank hold JSPR as of Q2 2024.

BFSG LLC reported no remaining Jasper Therapeutics position as of Q2 2024 after selling out during the quarter.
BFSG LLC sold 10 Jasper Therapeutics shares in Q2 2024, an estimated $294.
BFSG LLC first reported a position in Jasper Therapeutics in Q1 2024 and held it in 1 quarter.
BFSG LLC's Jasper Therapeutics position peaked at $294 in Q1 2024.
69 funds tracked by Wall St. Rank held Jasper Therapeutics as of Q2 2024.

Based on BFSG LLC's 13F filing for Q2 2024, filed 29 Jul 2024.